Exhibit 99.(a)(5)(v)

                            [Boston Scientific logo]


          BOSTON SCIENTIFIC COMPLETES TENDER OFFER FOR CARDIAC PATHWAYS



Natick, MA and Sunnyvale, CA (August 7, 2001) - Boston Scientific Corporation
(NYSE: BSX) and Cardiac Pathways Corporation today announced that Adam
Acquisition 2001 Inc., a wholly owned subsidiary of Boston Scientific, has
completed its cash tender offer for all the outstanding shares of common stock
of Cardiac Pathways. The tender offer expired, as scheduled, at 12:00 midnight,
New York City Time, on Monday, August 6, 2001. Based on a preliminary count,
8,645,082 shares of Cardiac Pathways were tendered and accepted for payment at a
price of $5.267 per share, resulting in Boston Scientific's ownership of
approximately 95.48% of the outstanding common stock of Cardiac Pathways. All
shares validly tendered and not withdrawn prior to the expiration of the offer
have been accepted for payment according to the terms of the offer.

Boston Scientific plans to merge Adam Acquisition 2001 Inc. into Cardiac
Pathways as soon as practicable. In the merger, each share of Cardiac Pathways
common stock not previously purchased in the tender offer will be converted into
the right to receive $5.267 in cash. Under applicable law, the proposed merger
is not subject to the approval of the remaining outstanding shareholders of
Cardiac Pathways. Once the proposed merger becomes effective, Cardiac Pathways
will become a wholly owned subsidiary of Boston Scientific.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical
devices. Boston Scientific's products are used in a broad range of
interventional medical specialties.

Cardiac Pathways designs, manufactures and markets minimally invasive systems
used by electrophysiologists to diagnose and treat cardiac tachyarrhythmias
(abnormally rapid heart rhythms), which if untreated can cause palpitations,
fainting and sudden cardiac arrest. Cardiac Pathways' products consist
principally of systems for performing ablation treatment (a nonsurgical,
minimally invasive technique for neutralizing heart tissue responsible for
starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating
the source of the tachyarrhythmia within the heart).




                  CONTACT: Milan Kofol (508-650-8569)
                           Investor Relations
                           Boston Scientific Corporation

                           Paul Donovan (508-650-8541)
                           Media Relations
                           Boston Scientific Corporation

                           Eldon Bullington (408-720-2864)
                           Vice President Finance and Chief Financial Officer
                           Cardiac Pathways Corporation